Washington R.E. Inv. Trust (WRE) is Trading Lower on Unusual Volume for December 21

Equities Staff |

Washington R.E. Inv. Trust (WRE) experienced unusually high volume on Dec. 21, as the stock lost 1.96% to a closing price of $26.97. The stock saw 858,560 shares trade hands over the course of the day on 3,753 trades. Given that the stock’s average daily volume over the last month has been 391,981 shares a day, this represents a pretty substantial spike over the norm.

Washington R.E. Inv. Trust has a P/B ratio of 2.33. It also has a P/E ratio of 61.3. The stock has traded between $30.15 and $23.78 over the last 52-weeks, its 50-day SMA is now $26.87, and its 200-day SMA $25.65.

Washington REIT is a real estate investment trust. It is engaged in the ownership and operation of income-producing real properties in the greater Washington metro region.

Headquartered in Washington, DC, Washington R.E. Inv. Trust has 181 employees and is currently under the leadership of CEO Paul T. McDermott.

For a complete fundamental analysis analysis of Washington R.E. Inv. Trust, check out Equities.com’s Stock Valuation Analysis report for WRE. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.


The Russell 3000 is not well known outside the world of finance, but it’s one of the strongest indices out there for getting a broad sense of the stock market. Unlike the better-known Dow Jones Industrial Average or S&P 500, membership on the Russell 3000 isn’t selected by committee. It’s simply the 3,000 most valuable companies in the country.

With 3,000 stocks making up the index, it gives a broad look at the markets, including the small-and mid-cap companies that aren’t on the Dow or the S&P 500. And with a rules-based system for determining membership, there’s no bias that could potentially limit membership. That’s why many financial professionals will turn to the Russell 3000 long before the better-known indices when trying to take the temperature of the market.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

Propanc Health Group Corp

Propanc Health Group Corp is an early stage healthcare company. It is engaged in developing new cancer treatments for patients, suffering from pancreatic and colorectal cancer.

Private Markets


A peer-to-Peer authentic photo marketplace disrupting the $10B commercial photography industry.

Ozobot by Evollve Inc

Ozobot is a world leader in compact super intelligent robots that entertain and educate through fun interactive gaming.